ByteDance Eyes Iluvatar, Baidu AI Chips Amid China’s AI Push 
Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
Oil Prices Tumble as U.S.-Iran Peace Deal Eases Supply Concerns 
Woodside Energy Denies Exxon Mobil Takeover Talks Amid LNG Growth Focus 
ASX Proposes New Share Dilution Limits for Public Takeovers 
Myanmar Economic Outlook Hit by Fuel Price Shock as World Bank Cuts Growth Forecast 
German Auto Suppliers Turn Bearish as Investment and Jobs Shift Overseas 
US Stock Futures Edge Higher Ahead of Key Federal Reserve Decision 
DOJ Clears Paramount Skydance-Warner Bros. Discovery Merger Without Conditions 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
China Industrial Output Beats Forecasts as Domestic Demand Weakens 
Gold Holds Gains as Oil Prices Retreat and Fed Decision Looms 
BOJ Rate Hike Expected to Boost Yen, Impact USD/JPY and Nikkei 
RBA Expected to Hold Interest Rates at 4.35% as Markets Watch AUD/USD and ASX 200 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
Gold Prices Surge Above $4,300 as US-Iran Peace Deal Weakens Dollar and Oil 
Australia’s Atlas Arteria Rejects IFM Global’s Increased A$7.4 Billion Takeover Offer 
Bristol Myers Squibb has been sued for $6. 4 billion for allegedly delaying a cancer drug. In the new lawsuit, it was claimed that the American multinational pharmaceutical company headquartered in New York improperly held up the development of a medicine for the treatment of non-Hodgkin's lymphoma.
The allegation against the pharma company
According to Reuters, it was alleged that Bristol Myers Squibb deliberately delayed the development so it can avoid paying $6.4 billion to Celgene Corp. shareholders. Bristol Myers acquired this drug manufacturing company in 2019.
Based on the complaint that was filed at the Manhattan federal court on Thursday, June 3, the company would have owed the said amount if it had received the approval from the U.S. Food and Drug Administration for specified deadlines for three drugs that Celgene had been developing.
In the filing, it was stated that the pharmaceutical company failed to use contractually required "diligent efforts" to get the FDA’s approval for the cancer drug called Breyanzi before the set deadline of Dec. 31, 2020. Now, with no approval before the deadline, the company was excused from paying the sum to Celgene.
It was reported that the lawsuit was filed by the UMB Bank NA, which is acting as a trustee for Celgene’s former shareholders. Bristol-Myers acquired Celgene under a $80.3 billion deal that was signed in November 2019.
Bristol Myers Squibb accused of misconduct
The former shareholders think that Bristol Myers did not exert efforts to beat the deadline when it was supposed to get the FDA’s approval for Breyanzi. They are suspecting that the company did this deliberately to avoid paying them, so they are accusing Bristol Myers of “blatant misconduct,” as per Fierce Pharma.
Finally, the case against Bristol Myers was recorded under 1:21-cv-04897 in the U.S. District Court-Southern New York. The shareholders that were represented by UMB Bank NA sued the pharma firm for breaching the CVR agreement through its failure to exert efforts to secure the needed approval from the FDA.
